Brand/Development Name: Capesaris
Principal Therapy Area: Cancer
GTx-758 (tradename, Capesaris) is a selective oestrogen receptor alpha agonist with potential for treating advanced prostate cancer (PC). Preclinical data show that this agent rapidly suppresses secretion of luteinising hormone (LH) by feedback inhibition on the pituitary, thereby inhibiting the production of androgens by the testes. In preclinical models, GTx-758 has demonstrated the potential to achieve medical castration to control PC, and also to prevent bone loss and hot flushes.
GTx-758 has potential to become the best-in-class androgen-deprivation therapy:
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focusing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for email@example.com